WO2025252137 - ANTIBODY-DRUG CONJUGATE
National phase entry is expected:
Publication Number
WO/2025/252137
Publication Date
11.12.2025
International Application No.
PCT/CN2025/099200
International Filing Date
05.06.2025
Title **
[English]
ANTIBODY-DRUG CONJUGATE
[French]
CONJUGUÉ ANTICORPS-MÉDICAMENT
[Chinese]
一种抗体药物偶联物
Applicants **
REMEGEN CO., LTD.
Inventors
WANG, Zhulun
FANG, Jianmin
CHEN, Hang
MIN, Xiaoshan
HUA, Sujun
WU, Yinan
JI, Shuya
WANG, Lili
LI, Yuanhao
JIANG, Jing
ZHANG, Wei
LIU, Shangyi
ZHAN, Xiuzhi
TANG, Haizhou
LIANG, Xin
LUO, Wenting
ZHANG, Qinbin
YE, Hui
Priority Data
202410732731.9
06.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6097 | |
| EPO | Filing, Examination, Granting | 115273 | |
| Japan | Filing, Examination, Granting | 4944 | |
| South Korea | Filing, Examination, Granting | 8190 | |
| USA | Filing, Examination, Granting | 26540 |
Total:
161,044
Contact Us
Abstract[English]
A use of a novel anti-CDCP-1 antibody or an antigen-binding fragment thereof, a linker compound, a deuterated payload, and a linker-payload compound in an antibody-drug conjugate, specifically relating to an anti-CDCP-1 antibody having good cell binding activity and affinity, and a linker and a payload compound that exhibit potent cytotoxicity and significant inhibitory activity on tumor cells. The antibody-drug conjugate prepared by using the anti-CDCP-1 antibody, the linker, and the payload compound can produce good inhibitory activity on tumors in vitro and in vivo, and has good safety. The described advantages are of great value for the development of the antibody-drug conjugate in clinical treatment.[French]
L'invention concerne l'utilisation d'un nouvel anticorps anti-CDCP-1 ou d'un fragment de liaison à l'antigène de celui-ci, d'un composé lieur, d'une charge utile deutérée et d'un composé lieur-charge utile, dans un conjugué anticorps-médicament, se rapportant spécifiquement à un anticorps anti-CDCP-1 présentant une bonne activité et une bonne affinité de liaison cellulaire, ainsi qu'un lieur et un composé de charge utile présentant une puissante cytotoxicité et une activité inhibitrice significative sur les cellules tumorales. Le conjugué anticorps-médicament préparé à l'aide de l'anticorps anti-CDCP-1, du lieur et du composé de charge utile, peut produire une bonne activité inhibitrice sur des tumeurs in vitro et in vivo, et présente une bonne sécurité. Les avantages décrits sont de grande valeur pour le développement du conjugué anticorps-médicament dans le traitement clinique.[Chinese]
一种新型抗CDCP-1抗体或其抗原结合片段、连接子化合物、氘代载荷、连接子-载荷化合物在抗体-药物偶联物中的应用，具体涉及有较好细胞结合活性和亲和力的抗CDCP-1抗体、对肿瘤细胞表现出较强毒性和显著抑制活性的连接子、载荷化合物，使用抗CDCP-1抗体、连接子、载荷化合物制备的抗体-药物偶联物在体内体外对肿瘤均可产生较好的抑制活性，并具有较好的安全性，以上优势对于抗体-药物偶联物在临床治疗中的发展具有重大价值。